TMCnet News
Mateon Therapeutics to Present at BIO CEO & Investor Conference on February 13, 2017SOUTH SAN FRANCISCO, Calif., Feb. 07, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today announced that it will present a company overview at the 19th Annual BIO CEO & Investor Conference in New York at 5:30 pm eastern time on Monday, February 13, 2017. A live webcast of the presentation will be available on the company’s website at www.mateon.com in “Events & Presentations” under the “Investors & ews” tab. A replay of the webcast will be available approximately one hour following the completion of the live event. About Mateon At Mateon, we believe that we can significantly improve cancer therapy by employing these two complementary approaches simultaneously. When utilized this way, VDAs obstruct existing blood vessels in the tumor leading to significant central tumor cell death while AAs prevent the formation of new tumor blood vessels. Mateon is committed to leveraging our intellectual property and the product development expertise of our highly skilled management team to enable VTT to realize its true potential and to bring much-needed new therapies to cancer patients worldwide. CONTACTS Investors: [email protected] 650-635-7000 Media: JPA Health Communications Nic DiBella [email protected] 617-945-5183 |